AR and prostate cancer: Our study confirms a direct and equivalent cell-cycle inhibitory and cytotoxic effect of enzalutamide on AR-expressing vascular endothelial cells as reported on prostate cancer cells, which is reinforced by its observed capacity to inhibit vascular tubule formation in vitro.